## Ann M Hopkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8539218/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer. Cells, 2022, 11, 735.	1.8	9
2	Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression. Cancers, 2022, 14, 1303.	1.7	2
3	Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1. Cancers, 2021, 13, 871.	1.7	7
4	Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers, 2021, 13, 1286.	1.7	1
5	Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death and Disease, 2021, 12, 763.	2.7	8
6	C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency. Biomedicines, 2021, 9, 1925.	1.4	4
7	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	2.3	8
8	Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models. Anticancer Research, 2019, 39, 1197-1204.	0.5	11
9	Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. Cancer Letters, 2019, 440-441, 23-34.	3.2	17
10	Cleaved JAM-A - connecting cancer and vascular disease?. Oncotarget, 2019, 10, 3831-3832.	0.8	1
11	Tight Junction Protein Junctional Adhesion Molecule-A Regulates the Expression of Receptor Tyrosine Kinase EPHA2 In Triple-Negative Breast Cancer Cells. Clinical Oncology and Research, 2019, , .	0.1	0
12	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774604.	1.4	11
13	Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species. Cellular Oncology (Dordrecht), 2018, 41, 35-46.	2.1	12
14	Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Research, 2018, 20, 140.	2.2	25
15	Adhesion in Physiological, Benign and Malignant Proliferative States of the Endometrium: Microenvironment and the Clinical Big Picture. Cells, 2018, 7, 43.	1.8	21
16	The Contribution of Ig-Superfamily and MARVEL D Tight Junction Proteins to Cancer Pathobiology. Current Pathobiology Reports, 2016, 4, 37-46.	1.6	0
17	Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalk. World Journal of Biological Chemistry, 2016, 7, 64.	1.7	9
18	Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Annals of Translational Medicine, 2015, 3, 184.	0.7	49

ANN M HOPKINS

#	Article	IF	CITATIONS
19	A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Research, 2014, 16, R19.	2.2	58
20	Ductal barriers in mammary epithelium. Tissue Barriers, 2013, 1, e25933.	1.6	21
21	The Molecular Aspects of Tight Junctions. Cancer Metastasis - Biology and Treatment, 2013, , 1-27.	0.1	0
22	Lipid Raft Association Restricts CD44-Ezrin Interaction and Promotion of Breast Cancer Cell Migration. American Journal of Pathology, 2012, 181, 2172-2187.	1.9	66
23	Lipid rafts are disrupted in mildly inflamed intestinal microenvironments without overt disruption of the epithelial barrier. American Journal of Physiology - Renal Physiology, 2012, 302, G781-G793.	1.6	32
24	An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. Journal of Experimental and Clinical Cancer Research, 2011, 30, 45.	3.5	11
25	Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Research, 2011, 13, R31.	2.2	104
26	Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. Journal of Pharmacy and Pharmacology, 2010, 54, 341-347.	1.2	39
27	Tight Junctions: A Barrier to the Initiation and Progression of Breast Cancer?. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-16.	3.0	70
28	JAMâ€A expression positively correlates with poor prognosis in breast cancer patients. International Journal of Cancer, 2009, 125, 1343-1351.	2.3	115
29	Treatment of Thoracic Esophageal Anastomotic Leaks and Esophageal Perforations with Endoluminal Stents: Efficacy and Current Limitations. Journal of Gastrointestinal Surgery, 2008, 12, 1168-1176.	0.9	154
30	Myosin II regulates the shape of three-dimensional intestinal epithelial cysts. Journal of Cell Science, 2008, 121, 1803-1814.	1.2	49
31	Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors. American Journal of Physiology - Renal Physiology, 2007, 292, G806-G817.	1.6	50
32	Desmoglein-2: A Novel Regulator of Apoptosis in the Intestinal Epithelium. Molecular Biology of the Cell, 2007, 18, 4565-4578.	0.9	105
33	Interferonâ€Î³ induces internalization of epithelial tight junction proteins via a macropinocytosisâ€like process. FASEB Journal, 2005, 19, 923-933.	0.2	319
34	Epithelial cell spreading induced by hepatocyte growth factor influences paxillin protein synthesis and posttranslational modification. American Journal of Physiology - Renal Physiology, 2004, 287, G886-G898.	1.6	19
35	RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. American Journal of Physiology - Cell Physiology, 2004, 287, C327-C335.	2.1	199
36	ICAM-1: targeted docking for exogenous as well as endogenous ligands. Advanced Drug Delivery Reviews, 2004, 56, 763-778.	6.6	80

ANN M HOPKINS

#	Article	IF	CITATIONS
37	Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis-Independent Mechanisms. Journal of Immunology, 2003, 171, 6164-6172.	0.4	793
38	Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. Journal of Cell Science, 2003, 116, 725-742.	1.2	184
39	Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia. Gastroenterology, 2001, 121, 566-579.	0.6	186
40	Modulation of tight junction structure and function by cytokines. Advanced Drug Delivery Reviews, 2000, 41, 303-313.	6.6	160
41	Modulation of tight junction function by G protein-coupled events. Advanced Drug Delivery Reviews, 2000, 41, 329-340.	6.6	56
42	Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. Biochemical and Biophysical Research Communications, 2000, 279, 808-813.	1.0	246